Financial reports
10-Q
2022 Q1
Quarterly report
12 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
10-K
2021 FY
Annual report
30 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
10-Q
2021 Q2
Quarterly report
12 Aug 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
13 Nov 20
10-Q
2020 Q2
Quarterly report
18 Sep 20
Current reports
8-K
Completion of Acquisition or Disposition of Assets
31 May 22
8-K
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
12 May 22
8-K
Tender and Support Agreement
19 Apr 22
8-K
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
19 Apr 22
8-K
Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results
30 Mar 22
8-K
Departure of Directors or Certain Officers
1 Mar 22
8-K
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
9 Feb 22
8-K
Departure of Directors or Certain Officers
1 Feb 22
8-K
Nilesh Kumar, Ph.D. departs Board of Directors upon transition to new role at Wellington Management
21 Dec 21
8-K
Regulation FD Disclosure
14 Dec 21
Registration and prospectus
15-12B
Securities registration termination
10 Jun 22
25-NSE
Exchange delisting
31 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
31 May 22
POS AM
Prospectus update (post-effective amendment)
31 May 22
SC 14D9/A
Tender offer solicitation (amended)
31 May 22
SC TO-T/A
Third party tender offer statement (amended)
31 May 22
SC TO-T/A
Third party tender offer statement (amended)
20 May 22
SC 14D9/A
Tender offer solicitation (amended)
20 May 22
Other
EFFECT
Notice of effectiveness
2 Jun 22
EFFECT
Notice of effectiveness
16 Sep 21
UPLOAD
Letter from SEC
13 Sep 21
CORRESP
Correspondence with SEC
13 Sep 21
EFFECT
Notice of effectiveness
7 Aug 20
CERT
Certification of approval for exchange listing
6 Aug 20
CORRESP
Correspondence with SEC
4 Aug 20
CORRESP
Correspondence with SEC
4 Aug 20
CORRESP
Correspondence with SEC
3 Aug 20
UPLOAD
Letter from SEC
24 Jul 20
Ownership
SC 13G/A
venBio Global Strategic Fund II L.P.
7 Jun 22
SC 13D/A
GARDNER LEWIS ASSET MANAGEMENT L P
7 Jun 22
SC 13D/A
Novo Holdings A/S
3 Jun 22
SC 13D
GARDNER LEWIS ASSET MANAGEMENT L P
3 Jun 22
4
MICHAEL POWELL
31 May 22
4
Keith T. Flaherty
31 May 22
4
Oren Isacoff
31 May 22
4
Peter Colabuono
31 May 22
4
Joy Yan
31 May 22
4
Robert Dolski
31 May 22